2 - 4 June 2020
9th Annual Biologics Manufacturing Korea 2020
Songdo, South Korea
Don't Miss Out on Biologics Manufacturing Korea 2020
300+
High Profile Attendees
50+
Experts Speakers
25+
Hours of Networking
20+
Case Studies
2020 Expected Attendee Profile
2019 Conference Agenda
Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate the development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.
Register Now!
2019 Speakers
Changwon Ji Daewoong Pharmaceutical
Executive Director- ProductionDaewoong PharmaceuticalKorea
Eun Young Yang Samsung Biologics
Executive Director CDO Business TeamSamsung BiologicsKorea
Robert Wonsang Yu Yuyu Pharma
Senior Vice President Yuyu PharmaSouth Korea
Kyoung E Kim CKD Pharm
Head of Strategy & Product DevelopmentCKD PharmKorea
Allen Ho JHL Biotech
Senior Director of Regulatory Technical CMCJHL BiotechTaiwanDr. Allen Ho joined JHL in September of 2016 with over 20 years of biotech experience in both research & development and regulatory affairs field. He is currentlyresponsible for all JHL IND clinical trial and future BLA submission, including JHL biosimilar products had successful submitted to phase 1 and phase 3 trials across
China, Europe, Asia and Australia. Prior to joining JHL, Dr. Ho was Director of Recombinant Protein Therapeutics in Pharmaessentia. Dr. Ho started his career as postdoctoral researcher at Academia Sinica, Taiwan and later assigned to integrated structural biology project in Strasbourg, France. Dr. Ho received his Ph.D. in
Chemistry from National Cheng-Kung University, Taiwan and had published various papers in biophysical and biochemical characterizations of proteins.
Shinya Takuma Chugai Pharma
PresidentChugai PharmaJapanShinya Takuma is the president of Chugai Pharma Manufacturing Co., Ltd., a subsidiary of Chugai Pharmaceutical since 2016. He received the M.S. in Biotechnology from Osaka University in 1989 followed by entering Chugai Pharmaceutical, where he mostly worked in the field of Bio-API process development, mainly USP, including working for James M. Piret in the University of British Columbia for 2 years.
Jin Cai (Jimmy) Lee Wuxi Biologics
Vice President, ManufacturingWuxi BiologicsChina
Jackal Tsou Mycenax Biotech Inc
Assistant Supervisor of Downstream Process DevelopmentMycenax Biotech IncTaiwan
Ruediger Mechsner Biotecs
CEOBiotecsSwitzerland
Sushant Sahastrabuddhe International Vaccine Institute
DirectorInternational Vaccine InstituteSouth KoreaDr. Sushant Sahastrabuddhe (MBBS, MPH, MBA) is the Director of Enteric Fever program at the International Vaccine Institute in Seoul, South Korea. Sushant is working in IVI since last 7 years and is leading the typhoid conjugate vaccine development with multiple manufacturers. Sushant is a medical graduate from India with Masters in Public Health from Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Before joining IVI, Sushant was working with National AIDS Research Institute (NARI) under the umbrella of Indian Council of Medical Research (ICMR) for 4 years. He has been involved in many phase I/II trials, including that of HIV vaccines. During previous assignment at NARI, Sushant was also involved in monitoring of the HIV sentinel surveillance under National AIDS Control Organization (NACO) for the western states of India. Sushant has wide experience in conducting and managing clinical trials and major public health initiatives. Dr. Sahastrabuddhe has over 10 publications and 2 book chapters.
Jina Kim Ministry of Food and Drug Safety
Scientific ReviewerMinistry of Food and Drug SafetySouth Korea
Shuichi Yamamoto Yamaguchi University Biomedical Engineering Center
DirectorYamaguchi University Biomedical Engineering CenterJapanHe received a BS degree in 1976, a MS in 1978 and a Ph. D in 1981 in the department of Food Science and technology at Kyoto University. He has been at Yamaguchi University since 1981 (Assistant Professor 1981-1988, Associate Professor 1989-1997, Professor 1998-present).
He teaches basic chemical engineering, biochemical engineering, separation engineering, transport phenomena, computer calculations for chemical engineering and process design.
His research interests are in the field of biochemical engineering, food engineering and mass transfer.
He received a 2004 research excellence award from the Society of Chemical Engineers Japan on “Engineering analysis of chromatography of proteins” and a 2005 research excellence award from Japan Society for Food Engineering on “Drying of liquid foods and inactivation of enzymes during drying”.
The following paper has been recognized in the “Top-75 most cited articles” as published in the IChemE journals 2006 – 2009. Shuichi Yamamoto and Ayako Kita, Rational design calculation method for stepwise elution chromatography of proteins, Trans.IChemE.Part C., Food and Bioproducts Processsing, Vol.84, C1, 72-77,2006
He has published more than 100 scientific papers. Among them, his monograph published in 1988 by Marcel Dekker “Ion-Exchange Chromatography of Proteins” is well-known. His chromatography model better known as “Yamamoto Model” and “Yamamoto number” has been employed by various biotech companies as well as by academic researchers. It is partly explained in Perry’s Chemical Engineering Handbook (pp.16-44, 16-45). A text book “Bioseparations Science and Engineering” by R.G.Harris et al. (Oxford press, 2003) describes in detail how to use his model with a Yamamoto number. His diffusion-based drying model is also called “Yamamoto model” as well, and has been used by many researchers.
He is a sub project leader of the National research project (Manufacturing Technology Association of Biologics).
He has also published several text books (chapters) for drying, mass transfer and adsorptions. He has been organizing a course “Basic Chemical Engineering“, for those who are working at chemical industries.
Currently he is Vice President of Asian Pacific Confederation of Chemical Engineers (APCChE) and a board member of World Chemical Engineering Council (WCEC) as a representative of the Society of Chemical Engineers, Japan (SCEJ).
He also serves as an editorial board member for the following journals; Separation Science and Technology, Preparative Biochemistry and Biotechnology, BioProcess International, Japan Journal of Food Engineering (Chief Editor).
For his university, he serves as the vice director of the university library and the director of Biomedical Engineering Center (YUBEC).
Takayuki Horiuchi Chitose Laboratory Corp
Member of the Board and Chief Technology OfficerChitose Laboratory CorpJapanIn 2002, Dr. Takayuki Horiuchi obtained Ph.D from Tokyo Metropolitan University. After joining Robert Wood Johnson Medical School, he started at the National Institute of Genetics. In 2006, he joined Chitose Laboratory Corp. At Chitose, in addition to supervising R & D, he is actively engaged in cell line development projects for manufacturing of biologics. He has held his current position as Member of the Board and CTO since 2013.
Hyun Joo An Chungnam National University
ProfessorChungnam National UniversityKoreaDr. Hyun Joo An is the director of the Asia-Pacific Glycomics Reference Site (AGRS), which develops and validates new analytical platforms for glycomic and glycoproteomic analysis in collaboration with government agencies and regional industry. Since 2011, Dr. An has been a professor at Chungnam National University. She received her BS and MS degrees from Inha University (Incheon, Korea) and her PhD from the University of California at Davis (Uniter states).Dr. An’s research focuses on bioanalytical mass spectrometry, with applications to glycomics, proteomics, glycoproteomics and glycolipidomics. Her specific research interests include bioanalytical method development, biopharmaceutical characterization, disease biomarker discovery, post mortem interval (PMI) marker discovery, brain glycome mapping, and glycobiology. She has authored and co-authored over 80 peer-reviewed publications on these subjects, and holds multiple related patents.
Minwoo Kim Hanmi Pharmaceuticals
Senior Researcher Process DevelopmentHanmi PharmaceuticalsKorea
David Lee Chief Executive Officer, CB Theranostics Inc
Chief Legal Officer, C-BIOMEXChief Executive Officer, CB Theranostics IncUSA
Paul Liu WuXi Biologics
Vice President, Biologics Development & Manufacturing; Advisor and former Head of BiosafetyWuXi Biologics
2020 Sponsors
Become a Sponsor!
Position your products & services in front of senior decision-makers from both the global and Korean biopharmaceutical industry at the Biologics Manufacturing Korea 2020. You get exclusive one-to-one access to key stakeholders to present your expertise through a variety of available thought leadership, branding and exhibitor packages.
Get in touch with us about your needs today!
Market Intelligence
An update in Korean Biopharmaceutical Facilities
A closer look at Korean & International CMOs
Survey Report of the past event
Venue & Accommodation
Songdo, South Korea
Songdo, also previously knowns as the Songdo International Business District was built from scratch, on reclaimed land from the Yellow Sea. The 1,500-acre development sits an hour outside of Seoul and is officially part of the city of Incheon, whose proximity to the international airport and the sea makes it both a transportation hub and the gateway to Korea.
It’s the heart of the greater Songdo city, and from its conception in 2001, the IBD was envisioned as a sustainable, low-carbon, and high-tech utopia. For Koreans, the city would have all the perks of Seoul—and more—but without the capital city’s air pollution, crowded sidewalks, and choking automotive traffic. And for foreign corporations looking for access to Asian economies, Songdo would be a glitzy business capital to rival Hong Kong and Shanghai.
English 
简体中文 
日本語 
한국어 
繁體中文